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Abstract
Background: Recurrent tuberculosis suggests potentially modifiable gaps in tuberculosis treatment and control activities.
The frequency of late recurrences following treatment completion has not been well-studied. We determined the frequency
of, and risk factors associated with, tuberculosis that recurs at least one year after completion of anti-tuberculosis therapy in
California.
Methods: The study population included culture-positive, pulmonary tuberculosis patients reported to the California
tuberculosis case registry from 1993 to 2007 who completed anti-tuberculosis therapy. A person with late recurrent
tuberculosis was defined as an individual that appeared in the registry more than once, determined by match on name and
date-of-birth, with at least one year between treatment completion of the first episode and treatment initiation of the
second episode.
Results: Among 23,517 tuberculosis patients, 148 (0.63%) had a late recurrence. Independent risk factors for recurrence
included: infection with a pyrazinamide mono-resistant isolate (adjusted hazard ratio, 2.93; p = 0.019); initiation of an
isoniazid- and rifampin-only treatment regimen (adjusted hazard ratio, 2.55; p = 0.0412); sputum smear-positive disease
(adjusted hazard ratio, 1.96; p = 0.0003); human immunodeficiency virus infection (adjusted hazard ratio, 1.81; p = 0.0149);
and birth in the United States (adjusted hazard ratio, 1.88; p = 0.0002). Infection with an isoniazid mono-resistant isolate was
protective (adjusted hazard ratio, 0.25; p = 0.0171).
Conclusions: The low frequency of late recurrent tuberculosis in California suggests that local TB control programs are
largely successful at preventing this adverse outcome. Nonetheless, we identified subpopulations at increased risk of late
tuberculosis recurrence that may benefit from additional medical or public health interventions.
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Introduction
Recurrent tuberculosis (TB) within a population suggests
potentially modifiable gaps in TB treatment and control activities.
We examined TB recurrence in California to assess its frequency
and to identify populations at increased risk that may benefit from
specific interventions. A recurrence of TB can be due to relapse or
re-infection [1]. To prevent relapse, TB treatment guidelines in
the United States (U.S.) recommend extended treatment for TB
cases with cavities on chest radiograph and delayed bacterial
clearance from sputum [2]. Re-infection is prevented when TB
transmission is averted. Populations at high risk of recurrent TB,
regardless of the recurrence mechanism, provide an important
group for early TB case-finding in high incidence settings [3].
In low incidence settings, targeted case-finding among populations
at high risk of recurrence could facilitate TB elimination by
preventing transmission. However, the value of additional follow-
up of TB patients depends on the probability of recurrence.
Although clinical trials have demonstrated the rarity of TB
relapse and re-infection in the U.S. and Canada [4,5], these studies
may not accurately reflect the incidence of recurrent TB under
usual TB program conditions. We conducted a large population-
based study of recurrent TB to provide a more robust estimate of its
frequency and associated risk factors. Because recurrent cases within
one year of treatment completion are defined as relapses and are not
reported as separate episodes in the U.S., we evaluated persons who
had a second TB episode after at least one year following treatment
completion of their previous episode. Thus, ‘‘late’’ recurrent TB, as
defined in this study, did not include second episodes identified
within twelve months after treatment completion, which is the most
common period monitored in clinical treatment trials [6]. Late
recurrences, not previously measured in large population-based
studies, are important because TB patients are not typically followed
beyond one year past treatment. If patient subgroups are at
increased risk of developing TB, enhanced follow-up of these
patients could prevent TB transmission.
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Methods
The study population included culture-positive, pulmonary TB
cases reported in California from January 1, 1993 to December
31, 2007. Cases were excluded if they did not complete treatment
or if initial drug susceptibility test results were not recorded.
Persons with late recurrent TB were those who had more than one
episode of culture-positive, pulmonary TB with at least one year
between the date treatment was completed for the first TB episode
and the date that treatment was initiated for the second TB
episode. We identified late recurrent TB by a deterministic match
using first name, last name, and date of birth. Minor mismatches
were tolerated in names or date of birth if sex, race, ethnicity, and
country of origin matched.
The local and state TB case registries were matched to the local
and state Acquired Immunodeficiency Syndrome (AIDS) registries
to determine HIV status of TB cases. To identify genotypes of pairs
of M. tuberculosis isolates from patients with late recurrent TB, the
national TB genotyping surveillance database, initiated in 2004 [7],
was queried. Drug resistance patterns of isolates from first and
second TB episodes were investigated from each TB case report.
We assessed changes in the frequency of late recurrences over
time with the Joinpoint Regression Program [8]. Statistical
analyses were performed using SAS version 9.1 (SAS Institute
Inc. Cary, North Carolina, USA). The main outcome variable was
a late recurrence, and time-to-recurrence was modeled using Cox
regression. Among sets of two dichotomous covariates that were
correlated (phi coefficient .0.3), only one variable of the set was
chosen as a predictor variable in the multivariate model. Decisions
to include one covariate among two or more correlated covariates
were based on efficiency (e.g. birth in U.S. was correlated with
more than one covariate) and the potential to subsequently
implement public health interventions among persons having the
characteristic measured by the covariate.
A multivariate Cox model was constructed by forwards stepwise
selection, and included, a priori, the variable for age at TB report
and covariates known to be associated with TB relapse: HIV co-
infection, and sputum smear-positive disease. Additional covari-
ates were added if, in univariate analysis, p#0.2 for association
with late recurrence. Age at TB report was retained in the
multivariate model. All other covariates were retained in the
multivariate model if their p-values were less than 0.05. We tested
interaction terms to determine whether they significantly im-
proved the models. We used a log-rank test of the likelihood ratio
to determine best model fit. Person-time-at-risk for late recurrence
was the time between the date therapy was completed for the first
(or single) episode, and the date that therapy started for the second
episode or the censor date, December 31, 2006 (to allow one year
for a recurrence through December 31, 2007) (Figure 1).
We tested the proportional hazards assumption by comparing
cumulative hazards of the multivariate model for strata of each
dichotomous variable and by Schoenfeld residual analysis for age.
To illustrate the increased risk of late recurrent TB for various
subpopulations, we modeled the proportion and timing of
recurrences for a 30-year-old population with a progressive
increase in numbers of risk factors.
Results
Frequency and description of recurrences
Among 23,517 culture-confirmed, pulmonary TB patients
who completed anti-TB therapy and were reported in California
during 1993–2007, 148 (0.63%) had a second episode of TB
reported at least one year after completion of therapy (Figure 2).
The majority of late recurrences occurred within three years
from treatment completion, and the hazard of recurrence
declined with time from treatment completion (Figure 3). Forty-
three TB patients had recurrences between months 12 and 24,
30 patients had recurrences between months 25 and 36, and 19
patients had recurrences between months 37 and 48 after
completing anti-TB therapy. The number of persons who
developed recurrent TB decreased over the study period:
patients whose TB recurrence occurred 25 to 36 months after
completion of therapy decreased by 15% per year from 1993–
2003 (p,0.05, Figure 4b). In addition, the number of patients
whose TB recurrence occurred 12 to 24 months after
completion of therapy appeared to decline, but the trend was
not statistically significant (Figure 4a).
Figure 1. Time-at-risk for late recurrent TB. The diagram depicts times related to treatment initiation and completion that define time-at-risk
and time-not-at-risk for late recurrent TB.
doi:10.1371/journal.pone.0026541.g001
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On univariate analyses, several factors were associated with
recurrent TB (Tables 1, 2, 3). Compared to persons with only one
episode of TB, persons with a late TB recurrence were more likely to
have the following characteristics during their initial TB episode:
sputum smear-positive disease; cavities on diagnostic chest radio-
graph; infection with a pyrazinamide mono-resistant isolate of M.
tuberculosis complex; and HIV co-infection (Table 2). Although
persons with late recurrent TB were more likely to have had a
documented culture conversion in their first TB episode, compared
to persons with one episode of TB (88% vs.79%, p = 0.040), the time
to culture conversion was longer for those with late recurrent TB
than those with only one TB episode (median = 71 days compared
to 54 days, Wilcoxon rank sums test p-value ,0.0001).
Of the 148 pairs of M. tuberculosis isolates from recurrent TB
patients, 147 had isoniazid and rifampin susceptibility test results
recorded for first and second TB episodes. One hundred thirty
three pairs of isolates (90%) had identical isoniazid and rifampin
susceptibility test results for first and second TB episodes: four
were MDR; two were isoniazid mono-resistant; and 127 were
sensitive to isoniazid and rifampin. Fourteen pairs of isolates (10%)
demonstrated changes in initial drug susceptibility patterns from
first to second TB episodes; 13 demonstrated increasing resistance,
indicating possible re-infection or acquired resistance (Table 4).
Genotype data were only available for two pairs of isolates. One of
these pairs revealed different DNA fingerprints for each isolate,
and one had the same DNA fingerprint.
Figure 2. Study population, 1993–2007. The figure shows the classification of patients in the study and the inclusion criteria. TB patients
included those who were alive at TB diagnosis with culture-positive, pulmonary TB (in both episodes for recurrent TB patients), and, had completed
anti-TB therapy. Patients were excluded if initial isoniazid or rifampin drug susceptibility test results were not documented, or, if the date of treatment
completion or date of initiation of treatment for a second TB episode was not documented. Percentages were calculated using the previous group
(previous box) as the denominator. One hundred forty eight persons in this study population had late recurrent TB, and 23,369 had one episode of TB
(see text for details). TB = tuberculosis.
doi:10.1371/journal.pone.0026541.g002
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Risk factors for TB recurrence
Although twenty-one variables had hazard ratios with p-
values#0.20 on univariate analysis (Tables 1, 2, 3), only thirteen
variables were tested in the full multivariate Cox proportional
hazards model. Five variables were excluded from the full model
because they were correlated with other variables. Since three
covariates, substance use, non-Hispanic black race, and Asian
race, were correlated with birth in the U.S. (phi coefficient = 0.33,
0.47, 20.45 respectively), only birth in the U.S. was included in
the multivariate model. Cavities on diagnostic chest radiograph
and sputum smear-positive disease are known risk factors for
relapse [3] and were correlated (phi coefficient = 0.32). Sputum
smear-positive disease had a higher univariate hazard ratio than
cavities on diagnostic chest radiograph, and was therefore included
in the multivariate model. Cavities on diagnostic chest radiograph
was also tested in the full model as a substitute for sputum smear-
positive disease and is discussed later. Private provider type was
correlated with self-administered therapy (phi coefficient = 0.4).
Self-administered therapy was included in the multivariate model
because it is a practice that is amenable to public health
intervention. Documented culture conversion and culture conver-
sion within 60 days were excluded from the multivariate model
due to a high proportion of missing data (Table 3).
The final model identified the following independent
risk factors, present in the first TB episode, for late recurrent
TB: pyrazinamide mono-resistance (adjusted hazards ratio
(aHR) = 2.93, 95% confidence interval (95% CI) = 1.19–7.19, p-
value (p) = 0.0190); an initial treatment regimen of isoniazid and
rifampin only (aHR = 2.55, 95% CI = 1.04–6.28, p = 0.0412);
sputum smear-positive disease (aHR = 1.96, 95% CI = 1.36–2.82,
p = 0.0003); birth in the U.S. (aHR = 1.88, 95% CI = 1.34–2.63,
p = 0.0002); and HIV co-infection (aHR = 1.81, 95% CI = 1.12–
2.91, p = 0.0149). An independent protective factor in the
multivariate model was infection with an isoniazid mono-resistant
M. tuberculosis strain (aHR = 0.25, 95% CI = 0.08–0.78,
p = 0.0171). Substituting cavities on diagnostic chest radiograph
for sputum smear-positive disease did not substantially change the
model (aHR for cavities on chest radiograph = 1.76, 95%
CI = 1.24–2.49, p = 0.0015).
The median time-on-treatment was significantly longer for the
initial episode of persons with late recurrences than persons with
one episode of TB (Table 3). Also, persons with isoniazid or
pyrazinamide mono-resistant TB were on treatment for longer
periods of time than those with pansusceptible TB (median = 9.4
and 9.9 vs. 7.8 months, respectively, Wilcoxon rank sum test p-
values,0.0001 for each comparison). In fact, all persons with late
recurrent TB and a pyrazinamide mono-resistant isolate in their
first episode were treated for at least nine months. Time-on-
treatment was not a statistically significant predictor of late
recurrence in the final multivariate model.
We modeled the risk of late TB recurrence, and its timing after
treatment completion, among a subpopulation of 30-year-old TB
patients with a progressive increase in numbers of risk factors
(Table 5). The probability of late TB recurrence one to three years
after completing treatment for the first TB episode was 1.42%
(95% CI = 0.72–2.1) for 30-year-old U.S.-born, HIV-positive
individuals who had sputum smear-positive TB (Table 5). The
probability of late TB recurrence one to three years after
completing treatment increased to 4.1% (95% CI = 0.1–7.91) for
30-year-old U.S.-born, HIV-positive persons who had sputum
smear-positive TB with a pyrazinamide mono-resistant isolate
(Table 5).
Discussion
This study is the first large population-based assessment of
recurrent TB in the U.S. Of 23,517 pulmonary, culture-positive
TB cases in California from 1993–2007, at least 148 (0.63%)
recurred after one or more years following treatment completion.
Populations at high risk for late recurrence represent a TB control
opportunity. Extending patient treatment may prevent recurrent
disease and detecting a second TB episode promptly may avert
transmission. Risk factors for late TB recurrence, present in the
first TB episode, included: infection with a pyrazinamide mono-
resistant isolate, initial treatment with isoniazid and rifampin only,
sputum smear-positive disease, HIV co-infection, infection with an
isoniazid sensitive, rather than an isoniazid mono-resistant isolate,
and birth in the U.S.
Figure 3. Cumulative hazards of recurrent TB. The figure shows the cumulative hazards of recurrent TB in the study population during the
study timeframe. Data for the first one year after treatment completion were not available (see text for details). Of 144 TB patients with complete
covariate data, 43 (30%) had a recurrence one to two years, 73 (51%) had a recurrence one to three years, and 108 (75%) had a recurrence one to five
years, after completing anti-TB therapy. TB = tuberculosis.
doi:10.1371/journal.pone.0026541.g003
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The proportion of late recurrent TB in California was similar to
findings from other surveillance studies and clinical trials in which
0.24% to 0.71% of TB patients had recurrences after twelve
months of completing treatment for the first TB episode [6,9].
However, this comparison may not be relevant because the TB
patient follow-up time, and the definition of a TB recurrence in
the comparison studies were different. While we cannot differen-
tiate acquired drug resistance from re-infection without additional
genotype data, our finding that 13 persons had increased drug
resistance in their second TB episode suggests that, at most, only a
small proportion (13 episodes = 9% of all recurrences and 0.05%
of all study cases) may have been related to drug resistance
acquired during treatment. The decline in the frequency of
persons with late recurrent TB, as shown by the decreasing
number of persons whose TB recurred within one or two years
from treatment completion through calendar time, is consistent
with declining TB incidence during the study period, and is
temporally associated with increased funding for TB programs by
Centers for Disease Control and Prevention [10], publication of
new guidance for TB control programs [11], and the widespread
use of highly active antiretroviral therapy for persons living with
HIV [12].
The importance of using recommended TB treatment
regimens is confirmed in this study; TB patients who were
initiated on only isoniazid and rifampin instead of the
recommended four-drug treatment regimen had a 2.5-fold
Figure 4. Trends in TB recurrences. Joinpoint regression program-generated trends using Poisson distribution. a. Number of persons with a
recurrent TB episode 12 to 24 months after treatment completion, by calendar year of first TB episode. The number of TB recurrences appeared to
decrease through time, 1993 to 2004, but the trend was not statistically significant. b. Number of persons with a recurrent TB episode 25 to 36
months after treatment completion, by calendar year of first TB episode. The number of TB recurrences declined through time, 1993 to 2003, with an
annual percent decrease of 15% (p-value,0.05).
doi:10.1371/journal.pone.0026541.g004
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increased risk of recurrence. The use of the recommended four-
drug treatment regimen increased during the study timeframe;
the proportion of TB cases initiated on the recommended four-
drug regimen was 62% in 1993 and 95% in 2006. Since 2000,
less than 1% of the study population was initiated on a two drug-
only treatment regimen. The increased use of the recommended
initial regimen may have also contributed to the decline in late
recurrent TB during the study timeframe.







ratio (95% CI) p-value
No. 148 23,369
Sex Male 102 (71) 14,852 (64) 1.41 (0.98–2.02) 0.064
Female 41 (29) 8,516 (36) Ref
Race/Ethnicity White 16 (11) 2,769 (12) Ref
Black 39 (26) 2,359 (10) 2.86 (1.99–4.13) ,0.0001
Hispanic 61 (41) 8,251 (35) 1.32 (0.95–1.83) 0.099
Asian/Pacific Islander 32 (22) 9,835 (42) 0.40 (0.27–0.60) ,0.0001
Age at report, years (median) 42.5 45.0 0.99 (0.99–1.00) 0.145
Birth in U.S. Yes 65 (44) 6,096 (27) 1.99 (1.44–2.75) ,0.0001
No 83 (56) 16,878 (73) Ref
Homelessness Yes 26 (18) 1,743 (7) 2.52 (1.65–3.86) ,0.0001
No 117 (79) 20,876 (89) Ref
Unk 5 (3) 750 (3)
Substance use{ Yes 43 (29) 3,857 (17) 2.05 (1.42–2.95) 0.0001
No 87 (59) 17,422 (75) Ref
Unk 18 (12) 2,090 (9)
Diagnosed in correctional facility Yes 2 (1) 777 (3) 0.38 (0.09–1.51) 0.168
No 146 (99) 22,550 (97) Ref
Definition of abbreviations: Ref = reference group; Unk = unknown or missing.
*Characteristic present in the first episode of patients with late recurrent TB (see text for details).
{Includes excess alcohol or injection drug use or non-injection drug use.
doi:10.1371/journal.pone.0026541.t001







ratio (95% CI) p-value
No. 148 23,369
Sputum AFB smear positive Yes 103 (70) 12,541 (54) 1.97 (1.37–2.83) 0.0002
No 41 (28) 9,533 (41) Ref
Unk 4 (3) 1,295 (6)
Cavitary chest radiograph Yes 51 (34) 5,739 (25) 1.63 (1.16–2.29) 0.0051
No 94 (64) 16,983 (73) Ref
Unk 3 (2) 647 (3)
HIV positive Yes 21 (14) 1,390 (6) 2.46 (1.55–3.90) 0.0001
No 127 (86) 21,979 (94) Ref
INH mono-resistance Yes 3 (2) 2,040 (9) 0.22 (0.07–0.67) 0.008
No 145 (98) 21,329 (91) Ref
PZA mono-resistance Yes 5 (3) 354 (2) 2.76 (1.13–6.74) 0.0255
No 143 (97) 23,015 (98) Ref
MDR Yes 4 (3) 285 (1) 2.56 (0.95–6.92) 0.064
No 144 (97) 23,084 (99) Ref
Definition of abbreviations: Ref = reference group; Unk = unknown or missing; HIV = Human immunodeficiency virus; INH = isoniazid; PZA = pyrazinamide; AFB = acid fast
bacilli; MDR = multidrug-resistant.
*Characteristic present in the first episode of patients with late recurrent TB (see text for details).
doi:10.1371/journal.pone.0026541.t002
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The independent risk factor with the highest hazard ratio was
pyrazinamide mono-resistance, a surrogate marker of tuberculosis
due to M. bovis [13]. Compared to M. tuberculosis, M. bovis is
associated with increased mortality [13,14,15], but the current
study is the first demonstration of its association with increased
TB recurrence. Although resistance to pyrazinamide necessitates
treatment extension [2,16], 26% of patients with pyrazinamide
mono-resistant isolates in this study were treated for less than nine
months. However, all five patients with pyrazinamide mono-
resistant isolates who had late recurrent TB were treated for at
least nine months in their first TB episode. Further investigation of
treatment strategies to prevent adverse outcomes associated with
TB caused by M. bovis, including relapse and death, may be
warranted.
Our study demonstrated that factors associated with relapse
soon after treatment completion were also associated with late
recurrence: sputum smear-positive disease, cavities on chest
radiograph, and HIV infection [5,17,18]. One possible strategy
to decrease recurrence is to extend therapy. The combination of
cavities on chest radiograph and delayed sputum culture
conversion is the primary indication for extended therapy
described in current U.S. TB treatment guidelines [2]. Recent
evidence has raised questions about the adequacy of six months of
rifamycin-based therapy for HIV co-infected patients and suggests
further investigation of extended treatment regimens for this group
[19,20].
Our study identified U.S. birth as a risk factor for TB
recurrence. Birth in the U.S. may have been a proxy for increased
risk of non-adherence to anti-TB therapy [21], increased risk for
re-exposure (e.g. among homeless or substance abusers), or other
unmeasured risk factors for recurrence (e.g. smoking)
[22,23,24,25]. An unexpected finding of this study was the
protective effect of isoniazid mono-resistant TB. It is possible that
isoniazid mono-resistant TB was a proxy for the use of six months









Initial drug regimen Standard 4drug 120 (81) 19,862 (85) Ref 0.021
Two-drug IR 7 (5) 361 (2) 2.46 (1.15–5.26) 0.591
Other regimen 21 (14) 3,146 (13) 0.88 (0.55–1.40)
Provider type{ Health dept 90 (61) 12,552 (54) 1.38 (0.99–1.92) 0.0553
Private/other 24 (16) 6,445 (28) Ref
Both 34 (23) 4,357 (19) 1.30 (0.88–1.90) 0.186
Anti-TB therapy administration{ SAT only 51 (34) 7,324 (31) 0.85 (0.60–1.19) 0.343
DOT only 59 (40) 11,049 (47) Ref
DOT+SAT 35 (24) 4,597 (20) 1.33 (0.91–1.95) 0.137
Unk 3 (2) 399 (2)
Time on anti-TB therapy, months (median) 9.02 mo. 8.34 mo. 1.03 (1.0–1.07) 0.052
Documented sputum culture conversion Yes 130 (88) 18,463 (79) 1.86 (1.03–3.36) 0.0395
No 12 (8) 2,657 (11) Ref
Unk 6 (4) 2,249 (10)
Culture conversion within 60 days Yes 47 (32) 9,306 (40) Ref
No 79 (53) 9,098 (39) 1.58 (1.10–2.26) 0.0137
Unk 22 (15) 4,965 (21)
Definition of abbreviations: Ref = reference group; Unk = unknown or missing; Standard 4drug = initial treatment with standard four drug regimen (isoniazid, rifampin,
pyrazinamide, ethambutol); Two-drug IR = initial treatment with isoniazid and rifampin only; DOT = directly observed therapy; SAT = self-administered therapy.
*Characteristic present in the first episode of patients with late recurrent TB (see text for details).
{3-level variable comparison.
doi:10.1371/journal.pone.0026541.t003
Table 4. Characteristics of patients with late recurrent TB











1 1.4 None INH
2 1.7 None INH
3 2.9 None INH
4 5.7 None INH
5 3.8 None INH
6 1.2 None INH
7 5.3 None RIF
8 1.5 None RIF
9 5.1 None RIF
10 2.1 None RIF
11 1.1 RIF INH, RIF
12 1.2 None INH, RIF
13 1.5 None INH, RIF
14 11.0 INH None
Definition of abbreviations: INH = isoniazid; RIF = rifampin.
doi:10.1371/journal.pone.0026541.t004
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of anti-TB therapy with pyrazinamide, recommended by national
guidelines [2], or, of extension of standard anti-TB drug therapy
[26].
Our findings should be interpreted in light of a number of study
limitations. We had no information about the true length of
follow-up (person-time at risk) for individuals who had a single TB
episode. The use of the censor date provided an approximation
that may have overestimated length of follow-up for the TB
patient population, resulting in an increasing underestimate of the
hazard of late recurrent TB over time. Also, the absolute number
of persons who developed a late recurrence is an underestimate
because some unmeasured number of persons may have
developed a second episode of TB after moving out of California.
The absence of sufficient genotyping data to assess the relative
frequency of relapse and re-infection in this population limits
inferences about acquired drug resistance and the evidence base
for recommending specific prevention interventions. Because this
study used the time between treatment initiation and treatment
completion dates as a surrogate for the time-on-treatment
covariate, the extent and duration of treatment interruptions were
unknown and likely differed by risk groups. Indeed, persons with
sputum smear-positive disease, HIV infection, or infection with
pyrazinamide mono-resistant isolates of M. tuberculosis were more
likely to have a longer time-on-treatment than persons without
these characteristics. Thus, the absence of evidence for time-on-
treatment as a predictor of late recurrent TB in this population
may reflect the limitation of the available data rather than the
actual lack of influence of treatment duration in the first TB
episode. Finally, the HIV status determination may have been
incomplete, leading to an underestimate of HIV co-infection
frequency in this population. However, we expect no difference in
the extent of TB/HIV co-infection underestimation for first
episodes of individuals with recurrent TB compared to individuals
with one episode of TB.
How should healthcare providers address the elevated risk of
TB recurrence in specific subpopulations? Post-treatment moni-
toring beyond one year may facilitate early TB case-finding among
those at high risk of recurrence, but clinical trial evidence to
support this intervention is limited. Implementation of post-
treatment monitoring varies in California, by local TB programs,
and elsewhere in the U.S. In one public health jurisdiction, TB
clinic appointments at six- but not twelve- months after treatment
completion facilitated early case-finding [27], suggesting that the
effectiveness of post-treatment monitoring may wane as the time
from treatment completion increases.
On the other hand, there is precedent for routine post-treatment
follow-up of TB patients at increased risk of recurrence.
Individuals who complete treatment for MDR-TB are monitored
for at least 24 months to identify potential relapse [16]. Also, U.S.
guidelines recommend close post-treatment monitoring of HIV-
infected patients who are at high risk of re-exposure to TB [28].
Additional data are needed to assess the effectiveness of different
post-treatment follow-up strategies to detect recurrent TB early
and prevent transmission.
In summary, this study provides a minimal estimate of the
frequency of late TB recurrence in a low incidence setting, and
suggests populations that may benefit from additional medical and
public health interventions or further investigation. Additionally,
our findings raise questions about the adequacy of treatment for
HIV-positive TB patients and TB patients with pyrazinamide
mono-resistant isolates. Investigation of treatment extension and
the utility of extended follow-up in specific patient groups at high
risk of recurrence may be warranted.
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